JP2003503504A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003503504A5 JP2003503504A5 JP2001507845A JP2001507845A JP2003503504A5 JP 2003503504 A5 JP2003503504 A5 JP 2003503504A5 JP 2001507845 A JP2001507845 A JP 2001507845A JP 2001507845 A JP2001507845 A JP 2001507845A JP 2003503504 A5 JP2003503504 A5 JP 2003503504A5
- Authority
- JP
- Japan
- Prior art keywords
- pyrimidin
- thieno
- composition
- compound
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 description 38
- 239000000203 mixture Substances 0.000 description 25
- 208000016285 Movement disease Diseases 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 229910052739 hydrogen Inorganic materials 0.000 description 12
- 239000001257 hydrogen Substances 0.000 description 12
- 125000000217 alkyl group Chemical group 0.000 description 11
- 208000035475 disorder Diseases 0.000 description 10
- 150000003839 salts Chemical class 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 8
- 150000002431 hydrogen Chemical class 0.000 description 7
- 208000018737 Parkinson disease Diseases 0.000 description 6
- 125000003118 aryl group Chemical group 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- 102000000033 Purinergic Receptors Human genes 0.000 description 5
- 108010080192 Purinergic Receptors Proteins 0.000 description 5
- -1 thieno [3,2-d] pyrimidin-2-yl Chemical group 0.000 description 5
- 102000009346 Adenosine receptors Human genes 0.000 description 4
- 108050000203 Adenosine receptors Proteins 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 206010034010 Parkinsonism Diseases 0.000 description 4
- 125000004093 cyano group Chemical group *C#N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 150000002367 halogens Chemical class 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 208000015122 neurodegenerative disease Diseases 0.000 description 4
- 230000004112 neuroprotection Effects 0.000 description 4
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical group OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 3
- 208000027089 Parkinsonian disease Diseases 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 210000004227 basal ganglia Anatomy 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 2
- 125000001054 5 membered carbocyclic group Chemical group 0.000 description 2
- 125000004008 6 membered carbocyclic group Chemical group 0.000 description 2
- 125000001960 7 membered carbocyclic group Chemical group 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 208000000094 Chronic Pain Diseases 0.000 description 2
- 208000012661 Dyskinesia Diseases 0.000 description 2
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 2
- 208000001089 Multiple system atrophy Diseases 0.000 description 2
- 208000008238 Muscle Spasticity Diseases 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 208000018839 Wilson disease Diseases 0.000 description 2
- BEHFCCCUBYKLIL-UHFFFAOYSA-N [2-(3-hydroxypropylamino)thieno[3,2-d]pyrimidin-4-yl]-thiophen-2-ylmethanone Chemical compound C=12SC=CC2=NC(NCCCO)=NC=1C(=O)C1=CC=CS1 BEHFCCCUBYKLIL-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 208000005298 acute pain Diseases 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 125000005597 hydrazone group Chemical group 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 230000001898 pallidal effect Effects 0.000 description 2
- 208000021090 palsy Diseases 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 208000018198 spasticity Diseases 0.000 description 2
- UNVLJXWEPJUHJU-UHFFFAOYSA-N 1-benzyl-3-[2-[[4-(thiophene-2-carbonyl)thieno[3,2-d]pyrimidin-2-yl]amino]ethyl]urea Chemical compound C=1C=CC=CC=1CNC(=O)NCCNC(N=C1C=CSC1=1)=NC=1C(=O)C1=CC=CS1 UNVLJXWEPJUHJU-UHFFFAOYSA-N 0.000 description 1
- BCNVTWOLTPPWTA-UHFFFAOYSA-N 1-prop-2-enyl-3-[2-[[4-(thiophene-2-carbonyl)thieno[3,2-d]pyrimidin-2-yl]amino]ethyl]urea Chemical compound C=12SC=CC2=NC(NCCNC(=O)NCC=C)=NC=1C(=O)C1=CC=CS1 BCNVTWOLTPPWTA-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- AXCXYXQXMXRXFK-UHFFFAOYSA-N 3-methyl-n-[2-[[4-(thiophene-2-carbonyl)thieno[3,2-d]pyrimidin-2-yl]amino]ethyl]butanamide Chemical compound C=12SC=CC2=NC(NCCNC(=O)CC(C)C)=NC=1C(=O)C1=CC=CS1 AXCXYXQXMXRXFK-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 208000011990 Corticobasal Degeneration Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 208000002603 Dopa-responsive dystonia Diseases 0.000 description 1
- 206010073210 Dystonic tremor Diseases 0.000 description 1
- 102100027346 GTP cyclohydrolase 1 Human genes 0.000 description 1
- 101000862581 Homo sapiens GTP cyclohydrolase 1 Proteins 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- YHZVBPJLMKPEHB-UHFFFAOYSA-N [2-(1-hydroxypropan-2-ylamino)thieno[3,2-d]pyrimidin-4-yl]-thiophen-2-ylmethanone Chemical compound C=12SC=CC2=NC(NC(CO)C)=NC=1C(=O)C1=CC=CS1 YHZVBPJLMKPEHB-UHFFFAOYSA-N 0.000 description 1
- RDDZRWPAJRJYIB-UHFFFAOYSA-N [2-(2,3-dihydroxypropylamino)thieno[3,2-d]pyrimidin-4-yl]-thiophen-2-ylmethanone Chemical compound C=12SC=CC2=NC(NCC(O)CO)=NC=1C(=O)C1=CC=CS1 RDDZRWPAJRJYIB-UHFFFAOYSA-N 0.000 description 1
- FQFCKXXHGAHJRN-UHFFFAOYSA-N [2-(2-hydroxyethylamino)thieno[3,2-d]pyrimidin-4-yl]-(3-methylthiophen-2-yl)methanone Chemical compound C1=CSC(C(=O)C=2C=3SC=CC=3N=C(NCCO)N=2)=C1C FQFCKXXHGAHJRN-UHFFFAOYSA-N 0.000 description 1
- PGCHQXADUKRVDJ-UHFFFAOYSA-N [2-(2-hydroxyethylamino)thieno[3,2-d]pyrimidin-4-yl]-thiophen-2-ylmethanone Chemical compound C=12SC=CC2=NC(NCCO)=NC=1C(=O)C1=CC=CS1 PGCHQXADUKRVDJ-UHFFFAOYSA-N 0.000 description 1
- AWFDTAUYZWDHCT-UHFFFAOYSA-N [2-(3-imidazol-1-ylpropylamino)thieno[3,2-d]pyrimidin-4-yl]-(3-methylthiophen-2-yl)methanone Chemical compound C1=CSC(C(=O)C=2C=3SC=CC=3N=C(NCCCN3C=NC=C3)N=2)=C1C AWFDTAUYZWDHCT-UHFFFAOYSA-N 0.000 description 1
- UNEXEZQHKDRHHO-UHFFFAOYSA-N [2-(3-imidazol-1-ylpropylamino)thieno[3,2-d]pyrimidin-4-yl]-thiophen-2-ylmethanone Chemical compound N=1C(NCCCN2C=NC=C2)=NC=2C=CSC=2C=1C(=O)C1=CC=CS1 UNEXEZQHKDRHHO-UHFFFAOYSA-N 0.000 description 1
- SLRLHYPXCOIOJR-UHFFFAOYSA-N [2-(oxolan-2-ylmethylamino)thieno[3,2-d]pyrimidin-4-yl]-thiophen-2-ylmethanone Chemical compound N=1C(NCC2OCCC2)=NC=2C=CSC=2C=1C(=O)C1=CC=CS1 SLRLHYPXCOIOJR-UHFFFAOYSA-N 0.000 description 1
- IVQBRHHYYXDKNW-UHFFFAOYSA-N [2-(pyridin-2-ylmethylamino)thieno[3,2-d]pyrimidin-4-yl]-thiophen-2-ylmethanone Chemical compound N=1C(NCC=2N=CC=CC=2)=NC=2C=CSC=2C=1C(=O)C1=CC=CS1 IVQBRHHYYXDKNW-UHFFFAOYSA-N 0.000 description 1
- FAFSUKUFAUCLQF-UHFFFAOYSA-N [2-[2-(1h-imidazol-5-yl)ethylamino]thieno[3,2-d]pyrimidin-4-yl]-thiophen-2-ylmethanone Chemical compound N=1C(NCCC=2N=CNC=2)=NC=2C=CSC=2C=1C(=O)C1=CC=CS1 FAFSUKUFAUCLQF-UHFFFAOYSA-N 0.000 description 1
- YHZVBPJLMKPEHB-MRVPVSSYSA-N [2-[[(2r)-1-hydroxypropan-2-yl]amino]thieno[3,2-d]pyrimidin-4-yl]-thiophen-2-ylmethanone Chemical compound C=12SC=CC2=NC(N[C@@H](CO)C)=NC=1C(=O)C1=CC=CS1 YHZVBPJLMKPEHB-MRVPVSSYSA-N 0.000 description 1
- YHZVBPJLMKPEHB-QMMMGPOBSA-N [2-[[(2s)-1-hydroxypropan-2-yl]amino]thieno[3,2-d]pyrimidin-4-yl]-thiophen-2-ylmethanone Chemical compound C=12SC=CC2=NC(N[C@H](CO)C)=NC=1C(=O)C1=CC=CS1 YHZVBPJLMKPEHB-QMMMGPOBSA-N 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 125000000879 imine group Chemical group 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- KSMPRJOTCWUTKA-UHFFFAOYSA-N n-[2-[[4-(thiophene-2-carbonyl)thieno[3,2-d]pyrimidin-2-yl]amino]ethyl]acetamide Chemical compound C=12SC=CC2=NC(NCCNC(=O)C)=NC=1C(=O)C1=CC=CS1 KSMPRJOTCWUTKA-UHFFFAOYSA-N 0.000 description 1
- OEFMDZAGQUZCHX-UHFFFAOYSA-N n-[2-[[4-(thiophene-2-carbonyl)thieno[3,2-d]pyrimidin-2-yl]amino]ethyl]cyclohexanecarboxamide Chemical compound C1CCCCC1C(=O)NCCNC(N=C1C=CSC1=1)=NC=1C(=O)C1=CC=CS1 OEFMDZAGQUZCHX-UHFFFAOYSA-N 0.000 description 1
- 125000003544 oxime group Chemical group 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- XAMUDJHXFNRLCY-UHFFFAOYSA-N phenthoate Chemical compound CCOC(=O)C(SP(=S)(OC)OC)C1=CC=CC=C1 XAMUDJHXFNRLCY-UHFFFAOYSA-N 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9915437.9 | 1999-07-01 | ||
| GBGB9915437.9A GB9915437D0 (en) | 1999-07-01 | 1999-07-01 | Chemical compounds III |
| PCT/GB2000/002517 WO2001002409A1 (en) | 1999-07-01 | 2000-06-30 | Thieno- and furopyrimidine derivatives as a2a-receptor antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003503504A JP2003503504A (ja) | 2003-01-28 |
| JP2003503504A5 true JP2003503504A5 (https=) | 2007-08-09 |
| JP4346269B2 JP4346269B2 (ja) | 2009-10-21 |
Family
ID=10856458
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001507845A Expired - Fee Related JP4346269B2 (ja) | 1999-07-01 | 2000-06-30 | Ａ２ａレセプターアンタゴニストとしてのチエノおよびフロピリミジン誘導体 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6787541B1 (https=) |
| EP (1) | EP1192164B1 (https=) |
| JP (1) | JP4346269B2 (https=) |
| AT (1) | ATE302205T1 (https=) |
| AU (1) | AU5557800A (https=) |
| CA (1) | CA2370344C (https=) |
| DE (1) | DE60022042T2 (https=) |
| GB (1) | GB9915437D0 (https=) |
| WO (1) | WO2001002409A1 (https=) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7202279B1 (en) | 1998-02-11 | 2007-04-10 | Georgetown University | Cyclic dipeptides and azetidinone compounds and their use in treating CNS injury and neurodegenerative disorders |
| GB0100623D0 (en) * | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical compounds IV |
| GB0100620D0 (en) * | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical cokpounds V |
| GB0100624D0 (en) * | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical compounds VII |
| US20050239782A1 (en) * | 2001-04-18 | 2005-10-27 | Heintzelman Geoffrey R | Arylindenopyridines and related therapeutic and prophylactic methods |
| US6903109B2 (en) * | 2001-04-18 | 2005-06-07 | Ortho-Muniel Pharmaceutical, Inc. | Arylindenopyridines and related therapeutic and prophylactic methods |
| US6958328B2 (en) * | 2001-04-18 | 2005-10-25 | Ortho-Mcneil Pharmaceutical, Inc | Arylindenopyridines and related therapeutic and prophylactic methods |
| ITRM20010465A1 (it) * | 2001-07-31 | 2003-01-31 | Sigma Tau Ind Farmaceuti | Derivati della triazolil-imidazopiridina e delle triazolilpurine utili come ligandi del recettore a2a dell'adenosina e loro uso come medicam |
| CN101543497A (zh) * | 2002-01-28 | 2009-09-30 | 协和发酵工业株式会社 | 治疗运动疾病患者的方法 |
| US20040127510A1 (en) * | 2002-04-16 | 2004-07-01 | Heintzelman Geoffrey R. | Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods |
| US7429584B2 (en) | 2002-07-11 | 2008-09-30 | Bayer Pharmaceuticals Corporation | Furo[2.3-b]pyridine derivatives for the treatment of hyper-proliferative disorders |
| AU2003268184A1 (en) | 2002-08-23 | 2004-03-11 | Chiron Corporation | Pyrrole based inhibitors of glycogen synthase kinase 3 |
| TW200410975A (en) * | 2002-09-26 | 2004-07-01 | Nihon Nohyaku Co Ltd | New pesticide and method for using it, new substituted thienopyrimidine derivative, its intermediate, and method for producing it |
| JP2006514697A (ja) * | 2002-12-19 | 2006-05-11 | シェーリング コーポレイション | アデノシンＡ２ａレセプターアンタゴニストの使用 |
| EP1618108A2 (en) * | 2003-04-09 | 2006-01-25 | Biogen Idec MA Inc. | Triazolo[1,5-a]pyrimidines and pyrazolo[1,5-a]pyrimidines useful as a2a adenosine receptor antagonists |
| EP1615930A2 (en) | 2003-04-09 | 2006-01-18 | Biogen Idec MA, Inc. | Triazolotriazines and pyrazolotriazines useful as a2a adenosine receptor antagonists |
| US7674791B2 (en) | 2003-04-09 | 2010-03-09 | Biogen Idec Ma Inc. | Triazolopyrazines and methods of making and using the same |
| WO2004092173A2 (en) * | 2003-04-09 | 2004-10-28 | Biogen Idec Ma Inc. | A2a adenosine receptor antagonists |
| US20070010522A1 (en) * | 2003-04-09 | 2007-01-11 | Chi Vu | Triazolo[1,5-c]pyrimidines and pyrazolo[1,5-c]pyrimidines useful as a2a adenosine receptor antagonists |
| US7923448B2 (en) * | 2003-11-03 | 2011-04-12 | Cornell Research Foundation, Inc. | Purine receptor inhibition as a therapeutic strategy in spinal cord and brain |
| WO2005080377A1 (ja) * | 2004-02-20 | 2005-09-01 | Kirin Beer Kabushiki Kaisha | TGFβ阻害活性を有する化合物およびそれを含んでなる医薬組成物 |
| JP5089395B2 (ja) | 2004-10-29 | 2012-12-05 | バイオクライスト ファーマシューティカルズ， インコーポレイテッド | 治療用フロピリミジンおよびチエノピリミジン |
| US7674822B2 (en) | 2004-11-24 | 2010-03-09 | Wyeth | PTP1b inhibitors |
| CN101212968B (zh) * | 2004-12-17 | 2011-11-16 | 安那迪斯药品股份有限公司 | 3,5-二取代的和3,5,7-三取代的-3H-噁唑并以及3H-噻唑并[4,5-d]嘧啶-2-酮化合物及其前药 |
| CN102504001B (zh) * | 2004-12-17 | 2015-02-25 | 安那迪斯药品股份有限公司 | 3,5-二取代的和3,5,7-三取代的-3H-噁唑并以及3H-噻唑并[4,5-d]嘧啶-2-酮化合物及其前药 |
| JP2008537961A (ja) * | 2005-04-15 | 2008-10-02 | ボード、オブ、トラスティーズ、オブ、ミシガン、ステイト、ユニバーシティ | Ｇｐｃｒモジュレーター |
| ES2273599B1 (es) | 2005-10-14 | 2008-06-01 | Universidad De Barcelona | Compuestos para el tratamiento de la fibrilacion auricular. |
| GB0718434D0 (en) | 2007-09-21 | 2007-10-31 | Vernalis R&D Ltd | New chemical compounds |
| GB0718432D0 (en) | 2007-09-21 | 2007-10-31 | Vernalis R&D Ltd | New chemical compounds |
| WO2010008775A1 (en) * | 2008-06-23 | 2010-01-21 | Ligand Pharmaceuticals Inc. | Aminopyridopyrazinone derivatives for treating neurodegenerative diseases |
| GB0906579D0 (en) * | 2009-04-16 | 2009-05-20 | Vernalis R&D Ltd | Pharmaceuticals, compositions and methods of making and using the same |
| US20100093763A1 (en) * | 2008-10-13 | 2010-04-15 | Barbay J Kent | PHENYL SUBSTITUTED THIENO[2,3-d]PYRIMIDINES AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS |
| US20100093721A1 (en) * | 2008-10-13 | 2010-04-15 | Barbay J Kent | PHENYL AND HETEROARYL SUBSTITUTED THIENO[2,3-d]PYRIMIDINES AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS |
| US20100093723A1 (en) * | 2008-10-13 | 2010-04-15 | Barbay J Kent | HETEROCYCLYL AND CYCLOALKYL SUBSTITUTED THIENO[2,3 d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS |
| US20100093722A1 (en) * | 2008-10-13 | 2010-04-15 | Barbay J Kent | HETEROARYL AND PHENYL SUBSTITUTED THIENO[2,3-d]PYRIMIDINES AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS |
| JP5765239B2 (ja) | 2009-03-13 | 2015-08-19 | アドヴィナス・セラピューティックス・リミテッド | 置換縮合ピリミジン化合物 |
| WO2011133696A2 (en) | 2010-04-20 | 2011-10-27 | Regents Of The University Of Minnesota | Methods of suppressing atherosclerosis |
| CN102408433B (zh) * | 2011-10-20 | 2014-04-09 | 天津药物研究院 | 含嘧啶的肟类化合物、其制备方法和用途 |
| CN102503953B (zh) * | 2011-10-20 | 2014-02-19 | 天津药物研究院 | 肟类化合物 |
| US9013997B2 (en) * | 2012-06-01 | 2015-04-21 | Broadcom Corporation | System for performing distributed data cut-through |
| JP7114076B2 (ja) | 2015-12-22 | 2022-08-08 | シャイ・セラピューティクス・エルエルシー | がん及び炎症性疾患の処置のための化合物 |
| JP7514005B2 (ja) | 2017-06-21 | 2024-07-10 | シャイ・セラピューティクス・エルエルシー | がん、炎症性疾患、ラソパシー、及び線維性疾患の治療のためのｒａｓスーパーファミリーと相互作用する化合物 |
| CN111629728A (zh) * | 2017-08-31 | 2020-09-04 | 科尔沃斯制药股份有限公司 | 用于调节腺苷a2b受体和腺苷a2a受体的化合物和方法 |
| JP7407461B2 (ja) | 2018-12-19 | 2024-01-04 | シャイ・セラピューティクス・エルエルシー | がん、炎症性疾患、ｒａｓ病、及び線維性疾患の処置のためのｒａｓスーパーファミリーと相互作用する化合物 |
| US11806350B2 (en) * | 2020-11-19 | 2023-11-07 | Ildong Pharmaceutical Co., Ltd. | Prevention and/or treatment of CNS disorders |
| WO2025160538A1 (en) * | 2024-01-26 | 2025-07-31 | The Board Of Regents Of The University Of Texas System | Compositions and methods for treating hair graying and loss associated with aging |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX9800776A (es) | 1995-07-28 | 1998-04-30 | Abbott Lab | Furopiridina, tienopiridina, pirrolopiridina y compuestos de triazina, piridazina y pirimidina relacionados utiles para controlar la transmision sinaptica quimica. |
| EP0975345A1 (en) | 1997-11-26 | 2000-02-02 | Cerebrus Pharmaceuticals Limited | (-)-mefloquine to block purinergic receptors and to treat movement or neurodegenerative disorders |
| AU1688599A (en) | 1998-01-05 | 1999-07-26 | Eisai Co. Ltd. | Purine derivatives and adenosine a2 receptor antagonists serving as preventives/remedies for diabetes |
| US6187777B1 (en) | 1998-02-06 | 2001-02-13 | Amgen Inc. | Compounds and methods which modulate feeding behavior and related diseases |
| GB9819384D0 (en) | 1998-09-04 | 1998-10-28 | Cerebrus Ltd | Chemical compounds II |
| GB9819382D0 (en) | 1998-09-04 | 1998-10-28 | Cerebrus Ltd | Chemical compounds I |
| US6841549B1 (en) | 1999-07-02 | 2005-01-11 | Eisai Co., Ltd. | Condensed imidazole compounds and a therapeutic agent for diabetes mellitus |
-
1999
- 1999-07-01 GB GBGB9915437.9A patent/GB9915437D0/en not_active Ceased
-
2000
- 2000-06-30 WO PCT/GB2000/002517 patent/WO2001002409A1/en not_active Ceased
- 2000-06-30 CA CA2370344A patent/CA2370344C/en not_active Expired - Fee Related
- 2000-06-30 AT AT00940670T patent/ATE302205T1/de not_active IP Right Cessation
- 2000-06-30 DE DE60022042T patent/DE60022042T2/de not_active Expired - Lifetime
- 2000-06-30 AU AU55578/00A patent/AU5557800A/en not_active Abandoned
- 2000-06-30 JP JP2001507845A patent/JP4346269B2/ja not_active Expired - Fee Related
- 2000-06-30 EP EP00940670A patent/EP1192164B1/en not_active Expired - Lifetime
- 2000-06-30 US US09/958,948 patent/US6787541B1/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003503504A5 (https=) | ||
| CA2370344A1 (en) | Thieno- and furopyrimidine derivatives as a2a-receptor antagonists | |
| AU715380B2 (en) | Pyrazolopyrimidines for treatment of neuronal and other disorders | |
| RU2006128426A (ru) | Производные тиофенав в качестве ингибиторов снк 1 | |
| RU95113966A (ru) | Пиразолопиримидины, фармацевтическая композиция и способ лечения | |
| DE602006017261D1 (de) | Behandlung von neovaskulären augenerkrankungen, wie z.b. maculadegeneration, angioiden streifen, uveitis und makulaödemen | |
| WO2007130429A3 (en) | Histone deacetylase and tubulin deacetylase inhibitors | |
| CA2334200A1 (en) | Pyrrolo[2,3d]pyrimidine compositions and their use | |
| KR20150080013A (ko) | 운동성 질환에 걸린 환자의 치료용 조성물 | |
| DE502004011581D1 (de) | Verwendung von rotigotin zur behandlung von depressionen | |
| BR0311558A (pt) | composto ou sal farmaceuticamente aceitável do mesmo, processo para preparar o mesmo, métodos para afetar os receptores de glutamato metabotrópicos ligados a camp, para administrar uma quantidade eficaz de um composto e para tratar um distúrbio neurológico e psiquiátrico em um paciente, e, formulação farmacêutica | |
| EP4520398A3 (en) | Treatment of prostate cancer | |
| RU2007101685A (ru) | Модуляторы никотиновых ацетилхолиновых рецепторов альфа 7 и их терапевтические применения | |
| JP2006512324A5 (https=) | ||
| EP4442321A3 (en) | Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor | |
| ATE369355T1 (de) | Pyrimidinamid derivate und deren verwendung | |
| CA2522813A1 (en) | 2-alkynyl-and 2-alkenyl-pyrazolo-¬4,3-e|-1,2,4-triazolo-¬1,5-c|-pyrimidine adenosine a2a receptor antagonists | |
| CN102647986A (zh) | 治疗增殖性障碍和其它由bcr-abl、c-kit、ddr1、ddr2或pdgf-r激酶活性介导的病理学病症的方法 | |
| EP4599894A3 (en) | Methods of treating chronic spontaneous urticaria using a bruton s tyrosine kinase inhibitor | |
| IL318953A (en) | Combination treatments including metal channel activators | |
| JP2002535370A5 (https=) | ||
| Punt | New drugs in the treatment of colorectal carcinoma | |
| CA2835717A1 (en) | Method for treatment of solid malignancies including advanced or metastatic solid malignancies | |
| HRP20160005T1 (hr) | 2-feniletilamono derivati kao modulatori kalcijskih i/ili natrijskih kanala | |
| JP2015526475A5 (https=) |